Biotech IPOs: High Tide
This article was originally published in Start Up
Executive Summary
Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.
You may also be interested in...
Early-Stage Investments Propel Jump In Life Sciences Venture Capital
In some cases, early venture capital appears to be substituting for the public market in providing finance not only to start but also sustain companies in specialty pharma and in-licensing, development-only businesses. At least 200 capital groups took part in the 156 recorded A rounds, and 50 participated in more than one.
Early-Stage Investments Propel Jump In Life Sciences Venture Capital
In some cases, early venture capital appears to be substituting for the public market in providing finance not only to start but also sustain companies in specialty pharma and in-licensing, development-only businesses. At least 200 capital groups took part in the 156 recorded A rounds, and 50 participated in more than one.
2015 Exits: Biotech’s Big Year
Fewer companies went public in 2015 than during the peak year of 2014, but on average 2015’s US IPO crop raised more money and at better valuations. And thanks to a jump in private biotech acquisition volume and valuations, investors enjoyed a tremendous year for biotech exits.